Thermo Fisher Scientific has introduced the Gibco CTS Detachable Dynabeads CD4 and CTS Detachable Dynabeads CD8 to its Cell Therapy Systems (CTS) portfolio. These products enhance the isolation and activation of CD4+ and CD8+ T cells, addressing the critical need for balance in Chimeric Antigen Receptor (CAR)-T cell therapies. Designed to minimize cell stress while ensuring high purity and yield, the detachable beads incorporate an innovative active release mechanism compatible with cGMP standards, making them ideal for process development, clinical trials, and commercial manufacturing. The platform streamlines workflows by reducing downstream process time, ultimately enabling faster delivery of life-changing treatments, particularly for patients with complex conditions like blood cancers.
Thermo Fisher Scientific, with annual revenues exceeding $40 billion, is dedicated to improving global health through its diverse portfolio of innovative technologies. Its CTS Detachable Dynabeads platform aligns with the company's mission by offering modular, automated, and closed-cell therapy manufacturing solutions. Currently supporting over 200 clinical trials and approved therapies, the platform reflects Thermo Fisher’s commitment to accelerating biopharma innovation, overcoming challenges in cell therapy development, and helping manufacturers bring transformative therapies to market with greater speed and precision.
